TICKERNERD
Menu
MBRXMBRXHealthcare · Biotechnology

MBRX Stock Forecast: Moleculin Biotech, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$0.43
+6.25% on the day

The 3 Wall Street analysts covering Moleculin Biotech, Inc. hold a median 12-month price target of $22 — +5076.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.8M
Ticker Nerd rank
11 / 100
Median analyst target
$22
Analysts covering
3
Total return, dividends reinvested
1W
−80.6%
1M
−83.9%
YTD
−87.2%
1Y
−97.4%
From 52W high
−97.5%
From 52W low
+6.3%
$0
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MBRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Moleculin Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
11 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
99
Volatility
55
Accruals
39
Issuance
32
Revisions
27
Growth
26
Quality
16
Value
7
Momentum
6

Size (99): Smaller than most of the companies we track.

Momentum (6): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own Moleculin Biotech, Inc. — and when they’d sell — is the membership.

Wall Street

MBRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MBRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30Oct 25Jan 26Apr 26Jul 26MBRXHigh $31Median $22Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $10Median $22High $31

The green dot is the last close — the median target sits +5076.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Mar 2026HC Wainwright & Co.ReiteratesBuy$22
11 Dec 2025HC Wainwright & Co.MaintainsBuy—
10 Sept 2025HC Wainwright & Co.ReiteratesBuy—
27 Aug 2025HC Wainwright & Co.ReiteratesBuy—
18 June 2025HC Wainwright & Co.ReiteratesBuy—
9 June 2025HC Wainwright & Co.AssumesBuy$4.00
25 Mar 2025HC Wainwright & Co.ReiteratesBuy—
25 Mar 2025Maxim GroupUpgradeBuy—
24 Mar 2025HC Wainwright & Co.ReiteratesBuy—
3 Mar 2025HC Wainwright & Co.MaintainsBuy—
12 Nov 2024Maxim GroupMaintainsBuy—
12 Apr 2024Roth MKMMaintainsBuy—
26 Mar 2024Maxim GroupMaintainsBuy—
14 Dec 2023HC Wainwright & Co.InitiatesBuy—
18 Apr 2023Roth MKMMaintainsBuy—
24 Mar 2023OppenheimerReiteratesOutperform—
18 July 2022OppenheimerAssumesOutperform$14
17 Oct 2019OppenheimerInitiatesOutperform$2.00
14 Nov 2018Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

MBRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Moleculin Biotech, Inc. (MBRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 75% of US stocks

Price / sales
—
Price / book
0.1×

Cheaper than 90% of US stocks

EV / EBITDA
0.3×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−532.0%

Higher than 2% of US stocks

Return on assets
−76.1%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MBRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MBRXMoleculin Biotech, Inc.$2.8M
11
AZTRAzitra, Inc.$2.1M
29
OGENOragenics, Inc.$2.2M
19
VRAXVirax Biolabs Group Ltd.$2.1M
12
SLXNSilexion Therapeutics Corp.$2.0M
37
CLDICalidi Biotherapeutics, Inc.$2.0M
23
DCOYDecoy Therapeutics, Inc.$2.4M
18
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MBRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest MBRX news & analysis

Moleculin Announces Pricing of $9.3 Million Public Offering

GlobeNewsWire · 31 July 2026neutral

Moleculin Biotech announced the pricing of a best-efforts public offering of 12,376,667 shares of common stock (or pre-funded warrants) and warrants to purchase up to 37,130,001 shares, at a combined price of $0.75 per share and associated warrants. The offering is expected to close on or about August 3, 2026.

Why it matters — The offering will dilute existing shareholders while raising approximately $9.3 million in gross proceeds for the company's operations.

Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

GlobeNewsWire · 31 July 2026positive

Moleculin reported positive interim data from its MIRACLE trial for relapsed/refractory AML, showing a 37% blinded composite remission rate in patients who had previously failed venetoclax therapy, with the trial approaching the end of Part A.

Why it matters — This is significant for MBRX watchers because the data suggests MIRACLE's treatment may achieve substantially higher remission rates in venetoclax-failed patients, a difficult-to-treat population with very low published salvage rates.

FAQ

Frequently asked questions about MBRX stock

What is the MBRX stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Moleculin Biotech, Inc. have a median 12-month price target of $22, with estimates ranging from $10 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MBRX stock a buy right now?

Of the 3 analysts covering Moleculin Biotech, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Moleculin Biotech, Inc. 11 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MBRX?

As at 1 Aug 2026, Moleculin Biotech, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

Will MBRX stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +5076.5% from the last close, and Ticker Nerd's factor model ranks Moleculin Biotech, Inc. 11 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MBRX stock forecast for 2030?

No analyst covering Moleculin Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $31 over the next 12 months.

How has MBRX stock performed over the past year?

Moleculin Biotech, Inc. returned -97.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Moleculin Biotech, Inc. do?

Moleculin Biotech Inc. is a clinical-stage pharmaceutical company that primarily focuses on the development of oncology drug candidates.

What is the latest news on MBRX?

The most recent item we track (GlobeNewsWire, 31 July 2026): "Moleculin Announces Pricing of $9.3 Million Public Offering". Moleculin Biotech announced the pricing of a best-efforts public offering of 12,376,667 shares of common stock (or pre-funded warrants) and warrants to purchase up to 37,130,001 shares, at a combined price of $0.75 per share and associated warrants. The offering is expected to close on or about August 3, 2026.

Company

About Moleculin Biotech, Inc.

Moleculin Biotech Inc. is a clinical-stage pharmaceutical company that primarily focuses on the development of oncology drug candidates. Based in Houston, Texas, the company concentrates its efforts on addressing unmet medical needs related to cancer. Moleculin Biotech is notable for its diverse pipeline of drug candidates, which includes small molecules targeting key biological pathways involved in cancer cell proliferation and survival. The company leverages its novel technologies, such as its Immune/Transcription Modulary Technology, to develop potential treatments that can be more effective and less toxic than existing therapies. Moleculin Biotech's research and developments are particularly influential within the biotechnology and pharmaceutical sectors, contributing to advancements in cancer treatment and offering hope for new therapeutic options. Through its innovative approach to drug development, Moleculin Biotech Inc. plays a significant role in the broader scientific and medical community, aiming to translate groundbreaking research into practical treatments that can improve patient outcomes.

CEO Mr. Walter V. Klemp · 17 employees · United States · https://moleculin.com